Nutriband (NTRB) Stock Price, News & Analysis

Company Overview

Nutriband Inc. is a medical technology company focused on developing and commercializing transdermal and topical products. The company’s platform is designed to deliver active pharmaceutical ingredients through the skin, with applications in prescription medicines, over-the-counter products, consumer health, and veterinary care.

Nutriband also provides contract manufacturing and product development services for transdermal patches and related products. Its offerings include adhesive patches and other topical delivery formats, as well as formulation, manufacturing, packaging, and regulatory support for customers developing transdermal therapies.

The company’s proprietary AVERSA technology is intended to incorporate abuse-deterrent and tamper-resistant features into transdermal drug-delivery systems. Nutriband has highlighted an AVERSA Fentanyl product candidate designed to help reduce the risk of accidental or intentional misuse of fentanyl patches. The company is headquartered in Orlando, Florida, and is led by co-founder and Chief Executive Officer Gareth Sheridan.

Key Stats

• Today's Range: $6.20 to $6.44
• 50-Day Range: $4.34 to $8.99
• 52-Week Range: $2.80 to $9.19
• Volume: 22,233 shs
• Average Volume: 35,894 shs
• Market Capitalization: $76.61 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Reduce

Nutriband Stock Analysis - MarketRank™

Nutriband scored higher than 16% of companies evaluated by MarketBeat, and ranked 839th out of 894 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Reduce

Consensus Rating

Nutriband has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

Nutriband has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Nutriband is -11.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Nutriband is -11.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Nutriband has a P/B Ratio of 11.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.72% of the float of Nutriband has been sold short.

Short Interest Ratio / Days to Cover

Nutriband has a short interest ratio ("days to cover") of 3.55, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Nutriband has recently increased by 2.84%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nutriband does not currently pay a dividend.

Dividend Growth

Nutriband does not have a long track record of dividend growth.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 0.89

News Sentiment

Nutriband has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Nutriband this week, compared to 1 article on an average week.

MarketBeat Follows

2 people have added Nutriband to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Nutriband insiders have not sold or bought any company stock.

Percentage Held by Insiders

52.21% of the stock of Nutriband is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

19.70% of the stock of Nutriband is held by institutions.

Company Calendar

• Last Earnings: 9/04/2026
• Today: 11/01/2026
• Next Earnings (Estimated): 12/07/2026
• Fiscal Year End: 1/31/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:NTRB
• CIK: 1676047
• Web: nutriband.com
• Phone: (407) 377-6695
• Fax: N/A
• Employees: 3
• Year Founded: 2016

Profitability

• EPS (Trailing Twelve Months): ($0.53)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.23 million
• Net Margins: -430.35%
• Pretax Margin: -430.41%
• Return on Equity: -109.07%
• Return on Assets: -95.54%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.21
• Quick Ratio: 4.02

Sales & Book Value

• Annual Sales: $2.04 million
• Price / Sales: 37.55
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.55 per share
• Price / Book: 11.45

Miscellaneous

• Outstanding Shares: 12,160,000
• Free Float: 5,809,000
• Market Cap: $76.61 million
• Optionable: Not Optionable
• Beta: 2.17